Lupin Limited · NSE:LUPIN
Lupin — Q4 FY24 Earnings Presentation
22 slides from Lupin's earnings presentation, May 7, 2024
Slide 1: Exchange filing cover letter for Investor Presentation Q4 FY24
May 7, 2024 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation - Q4 FY24. Pursuant to Regulation 30(2)
Slide 2: Investor Presentation Q4 FY24
Investor Presentation Q4 FY24 May 7, 2024
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q4 FY24 Performance
er LUPIN Q4 FY24 Performance
Slide 5: Q4 FY24: Key Growth Metrics
Q4 FY24: Key Growth Metrics Strong execution on all fronts Key Metrics Business Performance INR mn India North America 48,951 mn 16,015 mn 19,006 mn Sales 8% YoY 23% YoY 13% YoY EMEA 9,968 mn 20.4% Growth Markets EBITDA1 Margin 5,093 mn 5,318 mn 16% YoY 17% YoY 65% YoY API ROW 3,594 mn 7.3% 2,581 mn
Slide 6: Q4 FY24: Key Developments
Q4 FY24: Key Developments Consistent trajectory of improved profitability Financials Pipeline First US FDA Sales and Adj. EBITDA* Trajectory Doxycycline Dronedarone 60,000 30.0% Generic of approval capsules Tablets 49,392 50,799 48,951 Oracea® 50,000 43,303 45,369 25.0% Business Development 40,000 2
Slide 7: Q4 FY24 Financial Snapshot
Q4 FY24 Financial Snapshot Sales Mix Key Financials INR in mn Revenue (In INR mn and %) Q4 FY24 Q4 FY23 Q3 FY24 North India, America, 16,015 , 19,006 , 33% Sales 48,951 43,303 50,799 39% API, 2,581 , EBITDA1 9,968 6,041 10,220 5% Growth ROW, EMEA, Markets, 938 , 5,318 , 5,093 , Net Income 3,5942 2,3
Slide 8: India: Outperforming market growth
India: Outperforming market growth Leveraging therapy leadership; Added 3 India business grew 8.3% YoY in Q4FY24 new divisions in last 12 months India Sales (INR mn) 16,384 16,915 17,251 #2 rank #3 rank #3 rank 16,015 Respiratory Diabetes Care Cardiac 14,786 • Chronic share ~62% of sales • Diagnosti
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to outperform Enabling end to end healthcare ecosystem and access IPM with key drivers in place for the patient Enhancing penetration and reach CHC Portfolio catering to GI, • Maximizing Chronic therapy focus Business Verticals VMS
Slide 10: North America: Delivering on Complex Generics
North America: Delivering on Complex Generics Leadership: 4.5% TRx Consistent ramp up in sales Growing Respiratory volume share in U.S.1 portfolio US Sales ($mn) 175 181 213 212 209 #3 #1 23.4% 28% in the US1 in 47 products2 Albuterol Arfomoterol Q4 Q1 Q2 Q3 Q4 market share market share Maintaining
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Consistent performance in developed markets Emerging Markets • Steady growth witnessed in key markets (UK & Germany) • BRL 51mn sales4 in Q4FY24 EU • Growth driven by higher Brazil • Rank 2nd in reference market3 NaMuscla® and inhalation products like Luforbec® • Revenu
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end-to-end capabilities Successful outcomes in last 12 months of MDIs, DPIs, Soft-Mist I
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) 2,300 Capex (INR mn) 15.0% Net debt/ Equity 4,500 4,255 15.0% 1,848 13.0% 4,200 3,679 3,764 3,567 1,800 0.20 3,900 3,600 13.0% 1,502 11.0% 3,300 3,050 11.0% 1,345 3,000 1,300 1,171 1,059 9.0% 2,700 9.0% 0.14 2,400 8.7% 7.0% 7.0% 2,100 8.1% 7.6% 0.1
Slide 14: P&L Highlights Q4 FY24
P&L Highlights Q4 FY24 % of % of YoY % of QoQ Amount in INR mn Q4FY24 Q4FY23 Q3FY24 Sales Sales Growth Sales Growth Sales 48,951 100.0% 43,303 100.0% 13.0% 50,799 100.0% -3.6% Other operating income 657 1.3% 998 2.3% -34.2% 1,175 2.3% -44.1% Total revenue 49,608 101.3% 44,301 102.3% 12.0% 51,974 102
Slide 15: P&L Highlights FY24
P&L Highlights FY24 YoY Amount in INR mn FY24 % of Sales FY23 % of Sales Growth Sales 196,563 100.0% 162,700 100.0% 20.8% Other operating income 3,545 1.8% 3,717 2.3% -4.6% Total revenue 200,108 101.8% 166,417 102.3% 20.2% Gross Profit 130,129 66.2% 94,902 58.3% 37.1% (excl. other operating income)
Slide 16: Lupin at a Glance
Lupin at a Glance
Slide 17: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY24 Sales) 11th Largest in 7th India Pharma 9% Largest Generic 3 rd the US Market Rank 34% INDIA Developed Company (by prescriptions3) Markets (by sales6) (by sales1) 37% Largest Largest US $2
Slide 18: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 19: Lupin's ESG Journey in FY24
Lupin’s ESG Journey in FY24 Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Risk Management Lupin has enhanced the scope, nature and boundary of disclosures and multiple actions delivered at ground level in FY24 Continuous Efforts for improving access
Slide 20: ESG: Ratings update in FY24
ESG: Ratings update in FY24 Committed to accountability and public disclosure of ESG initiatives and metrics Lupin has made progress in ratings in 2023 responses in both S&P Global CSA and featured as a Yearbook Member 2024 and also scored B in CDP Climate and C in Water Agency 2021 2022 2023 Trends
Slide 21: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards • ATD (Association of Talent • Vinita Gupta, named among India’s 20 Most Influential Women Development) BEST Award in Healthcare by 2022 BW Healthcare World • ‘Factories of the Future’ at the • Goa and Nagpur awarded Gold
Slide 22: Thank You
youtube.com/c/LupinGlobal twitter.com/LupinGlobal linkedIn.com/company/lupin facebook.com/LupinWorld/ Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 | www.lupin.com